Bipartisan congressional lawmakers have teamed up on another psychedelics amendment to appropriations legislation—this time seeking to give the Department of Defense (DOD) another $10 million to support clinical trials into the therapeutic potential of substances such as ibogaine and psilocybin.
According to the spending legislation passed last year, DOD has already been mandated to fund the $10 million trials to determine the value of psychedelics to active-duty military personnel.
In order to help the department fulfill its mission, a coalition of bipartisan House legislators is seeking to increase the amount of support it receives to broaden the scope of research.
Led by Rep. Morgan Luttrell (R-TX), a Navy SEAL veteran himself who has been candid about his own experience benefitting from ibogaine and 5‐MeO‐DMT, the amendment would transfer the $10 million to “enable DoD Wide psychedelic medical clinical trails for the Defense Health Program research, development, test and evaluation.”
Luttrell’s spokesperson told MEDCAN24 that if this amendment was adopted, then the funding would be “placed in the Defense Health Program Research and Development Line” within the DOD.
Reps. Dan Crenshaw (R-TX), Sara Jacobs (D-CA) and Nancy Mace (R-NC)—as well as Reps. Jack Bergman (R-MI) and Lou Correa (D-CA), who serve as co-chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus.
The House Rules Committee determines whether the amendment needs to be amended in order to allow it for consideration on Monday during an hearing.
Bipartisan lawmakers and stakeholders are continuing to make progress in the discussion over psychedelics as evidenced by this proposal.
For example, former U.S. House Speaker Newt Gingrich (R-GA) recently said the psychedelic ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options—and he intends to use his influence to advance the issue.
In a Fox News Interview this week, the Navy SEAL Veteran credited with killing Osama Ben Laden stated that psychedelic therapies have helped him to process his trauma during his military service. The veteran stressed that “it is effective” and it should be a treatment option.
That interview came days after the U.S. House of Representatives included an amendment to a spending bill from Correa and Bergman that would encourage VA to support research into the benefits of psychedelics in treating medical conditions commonly affecting military veterans.
Last month, meanwhile, U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.”
U.S. Department of Veterans Affairs (VA) Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. In April, Collins said he was open to the notion of the VA providing vouchers for veterans to use psychedelic medicine outside VA.
Collins also recently visited a facility conducting research on psychedelics, and he reiterated that it’s his “promise” to advance research into the therapeutic potential of the substances—even if that might take certain policy changes within the department and with congressional support.
The secretary’s visit to the psychedelics research center came about a month after the VA secretary met with a military veteran who’s become an advocate for psilocybin access to discuss the therapeutic potential of psychedelic medicine for the veteran community.
Collins also briefly raised the issue in a Cabinet meeting with President Donald Trump in April.
Meanwhile last month, bipartisan congressional lawmakers asked the VA head to meet with them to discuss ways to provide access to psychedelic medicine for military veterans.
In a letter sent to Collins, Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—co-chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus—said they were “encouraged by your recent remarks about the importance of pursuing research into psychedelic treatments and other alternative treatments to improve Veterans’ care.”
Correa and Bergman separately introduced a bill in April to provide $30 million in funding annually to establish psychedelics-focused “centers for excellence” at VA facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine.
—
MEDCAN24 tracks hundreds of marijuana, psychedelics, and drug policy legislation in state legislatures this year. Patreon subscribers who donate at least $25/month have access to the interactive maps and charts as well as our hearing calendar.
Discover more about the marijuana bills tracker. Become a patron on Patreon and you will have access.
—
Bergman has also expressed optimism about the prospects of advancing psychedelics reform under Trump, arguing that the administration’s efforts to cut spending and the federal workforce will give agencies “spines” to tackle such complex issues.
Kennedy, for his part, also said in April that he had a “wonderful experience” with LSD at 15 years old, which he took because he thought he’d be able to see dinosaurs, as portrayed in a comic book he was a fan of.
Kennedy criticised the FDA in October last year for its “repression of psychedelics,” and also a long list of issues that Kennedy said were akin to “a ‘war on health,'” which would cease under Trump.
In December, VA separately announced that it’s providing $1.5 million in funding to study the efficacy of MDMA-assisted therapy for veterans with PTSD and alcohol use disorder (AUD).
Last year, VA’s Yehuda also touted an initial study the agency funded that produced “stunning and robust results” from its first-ever clinical trial into MDMA therapy.
Shereef Enahal, the former VA under secretary for health who was appointed by Trump to lead HHS in January said it was “very encouraging”, that Trump had chosen Kennedy as his HHS leader and that Kennedy supported reform of psychedelics. And he hoped to work with him on the issue if he stayed on for the next administration, but that didn’t pan out.
Carlosemmaskype, Apollo and other photographers provided the images.
MEDCAN24 would not be possible without the support of readers. Consider a Patreon subscription if our marijuana advocacy journalism is what you use to keep informed.
